Prevalence of cognitive impairment using the Montreal Cognitive Assessment questionnaire among patients with systemic lupus erythematosus: a cross-sectional study at two tertiary centres in Malaysia

Abstract

Introduction

Cognitive impairment is a common neuropsychiatric manifestation of systemic lupus erythematosus (SLE). However, it is not routinely assessed for despite its high prevalence and significant disease burden.

Aims

This study aimed to determine the prevalence of mild cognitive impairment (MCI) using the Montreal Cognitive Assessment (MoCA) and its associated factors among patients diagnosed with SLE in Malaysia.

Methods

A total of 200 SLE patients were recruited prospectively from the outpatient clinics of two tertiary hospitals in Malaysia. Standardized clinical interview was utilized to obtain information on socio-demographic characteristics. All patients were then assessed using the MoCA questionnaire for presence of cognitive impairment; the Patient Health Questionnaire 9 (PHQ-9) for presence of depressive symptoms; and the Wong–Baker Faces Pain Scale (WBFPS) for severity of pain. The evaluation of disease activity and severity were performed by the treating rheumatologists and nephrologists using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and Systemic Lupus International Collaborating Clinics Damage Index (SLICC DI).

Results

The prevalence of MCI was 35%. The significant associated factors from the bivariate analysis were male gender (p = 0.04), educational level (p = 0.00), WBFPS score (p = 0.035) and anticardiolipin IgM (p = 0.01). Further analysis using logistic regression model found that male gender (OR = 7.43, 95% confidence interval 1.06–52.06, p = 0.04), lower educational level (OR = 4.4, 95% confidence interval 1.47–13.21, p = 0.01) and presence of anticardiolipin IgM (OR = 6.81, 95% confidence interval 1.45–32.01, p = 0.031) were associated with impaired MoCA scores. Also, increasing pain scores increased the risk of patients being affected by cognitive impairment.

Conclusion

Over one-third of patients with SLE in our cohort were found to have MCI. Risk factors included male gender, lower educational level, higher pain score and presence of anticardiolipin IgM. Physicians are encouraged to perform routine screening to detect cognitive dysfunction in patients with SLE in their clinical practice as part of a more comprehensive management.

Keywords

Cognitive impairment Montreal Cognitive Assessment tool systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Ainiala

Hietaharju

Loukkola

et al.

Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum 2001; 45: 419–423.

Rayes H

Tani

Kwan

et al.

What is the prevalence of cognitive impairment in lupus and which instruments are used to measure it? A systematic review and meta-analysis. Semin Arthritis Rheum 2018; 48: 240–255.

Unterman

Nolte

JES

Boaz

et al.

Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum 2011; 41: 1–11.

Govoni

Bortoluzzi

Padovan

et al.

The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J Autoimmun 2016; 74: 41–72.

Mok

Mak

. Neuropsychiatric damage in southern Chinese patients with systemic lupus erythematosus. Medicine (Baltimore) 2006; 85: 221–228.

Said

MSM

Bin Shudim

Mohamad

et al.

Subclinical memory dysfunction in Malaysian systemic lupus erythematosus patients: association with clinical characteristics and disease activity – a pilot study. Egypt Rheumatol 2016; 38: 189–194.

Meara

Davidson

Steigelman

et al.

Screening for cognitive impairment in SLE using the Self-Administered Gerocognitive Exam. Lupus 2018; 27: 1363–1367.

Kozora

Hanly

Lapteva

et al.

Cognitive dysfunction in systemic lupus erythematosus: past, present, and future. Arthritis Rheum 2008; 58: 3286–3298.

Hanly

Omisade

et al.

Screening for cognitive impairment in systemic lupus erythematosus. J Rheumatol 2012; 39: 1371–1377.

10.

Hanly

. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol 2014; 10: 338–347.

11.

Panopalis

Julian

Yazdany

et al.

Impact of memory impairment on employment status in persons with systemic lupus erythematosus. Arthritis Rheum 2007; 57: 1453–1460.

12.

Baker

Pope

. Employment and work disability in systemic lupus erythematosus: a systematic review. Rheumatology 2009; 48: 281–284.

13.

Adhikari

Piatti

Luggen

. Cognitive dysfunction in SLE: development of a screening tool. Lupus 2011; 20: 1142–1146.

14.

Dalrymple-Alford

MacAskill

Nakas

et al.

The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010; 75: 1717–1725.

15.

Dong

Kumar

Chan

et al.

The Montreal Cognitive Assessment (MoCA) is superior to the Mini-Mental State Examination (MMSE) for the detection of vascular cognitive impairment after acute stroke. J Neurol Sci 2010; 299: 15–18.

16.

Liang

Corzillius

Bae

et al.

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599–608.

17.

Davis DH, Creavin ST, Yip JL, et al. Montreal Cognitive Assessment for the diagnosis of Alzheimer’s disease and other dementias. Cochrane Database Syst Rev. Epub ahead of print 29 October 2015.

18.

Nasreddine

Phillips

Bédirian

et al.

The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695–699.

19.

Nantes

Dhaliwal

et al.

Performance of screening tests for cognitive impairment in systemic lupus erythematosus. J Rheumatol 2017; 44: 1583–1589.

20.

Ghee

Kooi

et al.

A review of metabolic syndrome research in Malaysia. Med J Malaysia 2016; 71: 20–28.

21.

Kroenke

Spitzer

Williams

. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16: 606–613.

22.

Sherina

Arroll

Goodyear-Smith

. Criterion validity of the PHQ-9 (Malay version) in a primary care clinic in Malaysia. Med J Malaysia 2012; 67: 309–315.

23.

Wong-Baker FACES Foundation. Wong-Baker FACES Pain Rating Scale. Retrieved 1 July 2016 with permission from http://www.WongBakerFACES.org. Originally published in Whaley & Wong’s Nursing Care of Infants and Children, 2002, Elsevier Inc.

24.

Bombardier

Gladman

Urowitz

et al.

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630–640.

25.

Hawker

Gabriel

Bombardier

et al.

A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus. J Rheumatol 1993; 20: 657–660.

26.

Mosca

Bombardieri

. Assessing remission in systemic lupus erythematosus. Clin Exp Rheumatol 2006; 24 (Suppl 43): S99–S104.

27.

Gladman

Hirani

Ibañez

et al.

Clinically active serologically quiescent systemic lupus erythematosus. J Rheumatol 2003; 30: 1960–1962.

28.

Gladman

Goldsmith

Urowitz

et al.

The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for systemic lupus erythematosus international comparison. J Rheumatol 2000; 27: 373–376.

29.

Kivity

Agmon-Levin

Zandman-Goddard

et al.

Neuropsychiatric lupus: a mosaic of clinical presentations. BMC Med 2015; 13: 1–11.

30.

Lam

BCC

Koh

GCH

Chen

et al.

Comparison of body mass index (BMI), body adiposity index (BAI), waist circumference (WC), waist-to-hip ratio (WHR) and waist-to-height ratio (WHtR) as predictors of cardiovascular disease risk factors in an adult population in Singapore. PLoS One 2015; 10: e0122985–e0122985.

31.

Knopman

Boland

Mosley

et al.

Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 2001; 56: 42–48.

32.

Murray

Yazdany

Kaiser

et al.

Cardiovascular disease and cognitive dysfunction in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012; 64: 1328–1333.

33.

Hanly

Hong

Smith

et al.

A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 728–734.

34.

Menon

Jameson-Shortall

Newman

et al.

A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 735–741.

35.

Ruiz-Irastorza

Crowther

Branch

et al.

Antiphospholipid syndrome. Lancet 2010; 376: 1498–1509.

36.

Conti

Alessandri

Perricone

et al.

Neurocognitive dysfunction in systemic lupus erythematosus: association with antiphospholipid antibodies, disease activity and chronic damage. PLoS One 2012; 7: e33824–e33824.

37.

Stern

. Cognitive reserve: implications for assessment and intervention. Folia Phoniatr Logop 2013; 65: 49–54.

38.

Parisi

Rebok

Xue

et al.

The role of education and intellectual activity on cognition. J Aging Res 2012; 2012: 20–24.

39.

Appenzeller

Cendes

Costallat

LTL

. Cognitive impairment and employment status in systemic lupus erythematosus: a prospective longitudinal study. Arthritis Rheum 2009; 61: 680–687.

40.

Waldheim

Elkan

A-C

Pettersson

et al.

Health-related quality of life, fatigue and mood in patients with SLE and high levels of pain compared to controls and patients with low levels of pain. Lupus 2013; 22: 1118–1127.

41.

Fischin

Chehab

Richter

et al.

Factors associated with pain coping and catastrophising in patients with systemic lupus erythematosus: a cross-sectional study of the LuLa-cohort. Lupus Sci Med 2015; 2: e000113–e000113.

42.

Kozora

Ellison

West

. Depression, fatigue, and pain in systemic lupus erythematosus (SLE): relationship to the American College of Rheumatology SLE neuropsychological battery. Arthritis Care Res 2006; 55: 628–635.

43.

Jarpa

Babul

Calderon

et al.

Common mental disorders and psychological distress in systemic lupus erythematosus are not associated with disease activity. Lupus 2011; 20: 58–66.

44.

Petri

Naqibuddin

Carson

et al.

Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus. J Rheumatol 2010; 37: 2032–2038.

45.

Denburg

Carbotte

Denburg

. Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37: 1311–1320.

46.

Gerosa

Poletti

Pregnolato

et al.

Antiglutamate receptor antibodies and cognitive impairment in primary antiphospholipid syndrome and systemic lupus erythematosus. Front Immunol 2016; 7: 5–10.

47.

Holliday

Navarrete

Hermosillo-Romo

et al.

Validating a computerized neuropsychological test. Lupus 2003; 12: 697–703.